Vestmark Advisory Solutions’s Ascendis Pharma A/S ASND Stock Holding History

Vestmark Advisory Solutions’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$698K	Sell	2,617 -3,109	-54%	-$726K	0.01%	1057
2026 Q1	$1.31M	Sell	5,726 -80	-1%	-$17.9K	0.01%	788
2025 Q4	$1.24M	Buy	+5,806	New	+$1.2M	0.02%	734

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vestmark Advisory Solutions's ASND Position: Q2 2026 in Review

Vestmark Advisory Solutions reduced its Ascendis Pharma A/S (ASND) stake by 54% in Q2 2026, selling an estimated $726K and leaving 2,617 shares worth $698K. The position accounts for 0.01% of the portfolio, ranked #1057.

Vestmark Advisory Solutions first reported a position in ASND in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.31M in Q1 2026. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Vestmark Advisory Solutions held 2,617 shares of Ascendis Pharma A/S worth $698K as of Q2 2026.
Vestmark Advisory Solutions sold 3,109 Ascendis Pharma A/S shares in Q2 2026, an estimated $726K.
Ascendis Pharma A/S made up 0.01% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #1057 holding.
Vestmark Advisory Solutions first reported a position in Ascendis Pharma A/S in Q4 2025 and has held it in 3 quarters since.
Vestmark Advisory Solutions's Ascendis Pharma A/S position peaked at $1.31M in Q1 2026.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.